Table 1 Baseline clinical characteristics at baseline and after three years in patients with hypertension

From: The relationship between continuation of exercise habit for three years and endothelial function in patients with hypertension

 

Control group

Regular exercise group

Variables

Baseline (n = 385)

3 years (n = 385)

Baseline (n = 254)

3 years (n = 254)

Age, yr

61 ± 9

 

64 ± 8 *

 

Men, n (%)

218 (56.6)

 

142 (55.9)

 

Body mass index, kg/m2

25.0 ± 3.8

25.0 ± 4.0

24.2 ± 3.1*

24.1 ± 3.3*

Heart rate, bpm

72 ± 13

70 ± 13†

71 ± 11

69 ± 13†

Systolic blood pressure, mmHg

135 ± 15

133 ± 15 †

134 ± 15

135 ± 15*

Diastolic blood pressure, mmHg

80 ± 10

78 ± 11 †

80 ± 11

78 ± 11†

Total cholesterol, mmol/L

5.17 ± 0.93

5.04 ± 0.80 †

5.17 ± 0.85

5.04 ± 0.88 †

Triglycerides, mmol/L

1.13 (0.89, 1.84)

1.22 (0.88, 1.65) †

1.23 (0.85, 1.73)

1.19 (0.82, 1.64) †

HDL-C, mmol/L

1.50 ± 0.39

1.53 ± 0.39 †

1.53 ± 0.41

1.53 ± 0.41

LDL-C, mmol/L

3.00 ± 0.75

3.00 ± 0.72†

3.03 ± 0.78

3.00 ± 0.75†

Creatinine, µmol/L

68.07 ± 18.56

71.60 ± 29.17†

68.07 ± 17.68

70.72 ± 20.33†

Fasting blood glucose, mmol/L

5.83 ± 1.05

5.83 ± 1.28

5.77 ± 1.05

5.72 ± 0.94

Hemoglobin A1c, %

5.9 ± 0.6

6.0 ± 0.7†

5.9 ± 0.6

5.9 ± 0.6

hsCRP, ng/mL

480 (255, 1010)

506 (240, 1145)

489 (282, 908)

525 (284, 1040)

Medical history, n (%)

 Hypertension

385 (100)

 

254 (100)

 

 Dyslipidemia

254 (66.3)

257 (66.8)

169 (66.5)

180 (70.9)

 Diabetes mellitus

77 (20.3)

82 (26.8)

45 (17.9)

48 (24.0)

Current Smoking, n (%)

50 (13.2)

44 (11.4)

23 (9.2)

21 (8.3)

Medication, n (%)

 Antihypertensive drugs

377 (97.9)

368 (95.6)

248 (97.6)

245 (96.5)

  Calcium channel blockers

255 (66.2)

252 (65.5)

164 (64.6)

175 (68.9)

  ARBs/ACEIs

255 (66.2)

265 (68.9)

176 (69.3)

160 (63.0)

  Aldosterone antagonists

13 (3.4)

18 (4.7)

4 (1.6)

6 (2.4)

 Lipid lowering drugs

140 (36.4)

157 (40.8)

84 (33.1)

101 (39.8)

 Anti-diabetic drugs

47 (12.2)

55 (14.3)

20 (7.9)

24 (9.5)

baPWV, cm/seconds

1600 (1394, 2017)

1601 (1407, 1996)

1567 (1440, 1979)

1590 (1444, 2534)

FMD, %

4.6 (3.0, 6.7)

4.4 (2.5, 6.4)

4.4 (2.7, 6.3)

4.5 (2.8, 7.2)†

  1. HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, hsCRP high sensitivity C-reactive protein, ARB angiotensin receptor blocker, ACE angiotensin converting enzyme inhibitor, baPWV brachial ankle pulse wave velocity, FMD flow-mediated vasodilation
  2. *P  < 0.05 vs Control group, †P <  0.05 vs Baseline